ClinicalTrials.gg
CompletedNCT04677959CONNECT2Updated Mar 14, 2023Results posted

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

A Phase 4 interventional study of Fluticasone propionate/salmeterol (FS) and Albuterol in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 46 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2023-03-14.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
40th of 146
427 · median 100
Started
2021
with 4 others
Phase 4
52 of 147
1 open now
Registered
137th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 40th largest by enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2021, is one of 52 in phase 4, and was the 137th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group.

The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for all participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among participants for all participants in both groups, to evaluate work productivity and activity impairment in asthma participants in both groups, to assess the usability and acceptability of the DS by participants in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Read the detailed description

Study duration will be approximately 27 weeks including a one-week screening period, 24 week treatment period, and a 2 week follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a documented diagnosis of asthma established at the center at the time of or the investigator confirms a diagnosis of asthma.
  • The participant is currently on treatment with a moderate- to high-dose inhaled (ICS) with long-acting beta agonist (LABA).
  • The participant has an Asthma Control Test score of less than 19 at the screening or baseline visit.
  • The participant is willing to discontinue all other maintenance ICS with LABA medications and rescue medications and replace them with the study-provided fluticasone propionate/salmeterol (FS) multidose dry powder inhaler with integrated electronic module (eMDPI) and Albuterol eMDPI, respectively, for the duration of the trial, if randomized to the Digital System group. All other asthma maintenance medications, except for ICS with LABA, may be continued.

    • Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • The participant is currently being treated prior to enrollment with a digital inhaler system, including the Digihaler system or an external "bolt on" digital system designed to monitor inhaler usage, such as the Propeller Health or Adherium systems.
  • The participant has any uncontrolled medical condition (treated or untreated) other than asthma, which in the view of the investigator would preclude participation.
  • The participant was hospitalized for severe asthma in the last 30 days.
  • The participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study.

    • Additional criteria apply, please contact the investigator for more information.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    Digital System (DS)

    DS group participants utilizing the eMDPI DS, including inhaler, smart device application (App), DHP (Cloud solution), and dashboard

    Drug: Fluticasone propionate/salmeterol (FS) · Drug: Albuterol

  • Active comparator
    Standard of Care (SoC) Group

    SoC group participants will be treated with their standard of care medications

    Drug: Standard of Care Asthma Medication · Drug: Standard of Care Rescue Medication

Interventions

  • DrugFluticasone propionate/salmeterol (FS)

    Drug pages: Fluticasone · Salmeterol Xinafoate

    FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

  • Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard

  • DrugStandard of Care Asthma Medication

    Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma

  • DrugStandard of Care Rescue Medication

    Current rescue medication

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control

    A well-controlled asthma was defined as an Asthma Control Test (ACT) score of greater than or equal to 20. Clinically important improvement in asthma control was defined by an increase of at least 3 ACT units from baseline. The ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The ACT included 5 items that assessed daytime and nighttime asthma symptoms, use of reliever medication, and impact of asthma on daily functioning. Each item in the ACT was scored on a 5-point scale ranging from 1 (poor control of asthma) to 5 (well control of asthma), with summation of all items providing scores ranging from 5 to 25. The scores span the continuum of poor control of asthma (score of 5) to complete control of asthma (score of 25), with a cutoff score of 19 and below indicating participants with poorly controlled asthma.

    Time frame: Week 24

Secondary outcomes

  1. Number of Discussions Between Participant and Investigational Center Healthcare Professional (iHCP) Regarding Inhaler Technique or Adherence

    Number of participants who had discussions with iHCP regarding inhaler technique or adherence are reported.

    Time frame: Baseline up to Week 24

  2. Number of Decreased Doses of Inhaled Medication

    Number of participants who received decreased dose of inhaled medication during the 24-week treatment period are reported.

    Time frame: Baseline up to Week 24

  3. Number of Increased Doses of Inhaled Medication

    Number of participants who received increased dose of inhaled medication during the 24-week treatment period are reported.

    Time frame: Baseline up to Week 24

  4. Number of Changes to Different Inhaled Medication

    Number of participants who received different inhaled medication during the 24-week treatment period are reported.

    Time frame: Baseline up to Week 24

  5. Number of Additional Inhaled Medication

    Number of participants who received additional inhaled medication during the 24-week treatment period are reported.

    Time frame: Baseline up to Week 24

  6. Number of Addition of a Systemic Corticosteroid Medication for Asthma Therapy

    Number of participants who received additional systemic corticosteroid medication for asthma therapy during the 24-week treatment period are reported.

    Time frame: Baseline up to Week 24

  7. Frequency of Intervention to Manage Comorbid Conditions Associated With Poor Asthma Control

    Number of participants with different frequency of intervention to manage comorbid conditions such as Gastroesophageal Reflux Disease (GERD) and Sinusitis are reported.

    Time frame: Baseline up to Week 24

  8. Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group

    Time frame: Baseline, Week 24

  9. Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group

    Number of days a participant did not use the rescue medication in a week are reported.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group

    Adherence to maintenance treatment was defined as the percentage of actual inhalation doses taken out of the total number of inhalation doses prescribed over the 24- week treatment period.

    Time frame: Baseline, Week 24

  11. Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24

    The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ concern is a 6-item scale assessing participant's concerns about potential adverse consequences (range: 1=strongly disagree to 5=strongly agree). Participants indicated their degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).

    Time frame: Baseline, Week 24

  12. Change From Baseline in BMQ Necessity Subscale Score at Week 24

    The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ necessity is a 5-item scale assessing participant's beliefs about necessity of medications for controlling disease. Participants indicated degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).

    Time frame: Baseline, Week 24

  13. Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24

    The BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. Only one item assesses illness comprehensibility or coherence of illness (Item 7: How well do you feel you understand your illness?). This item was rated using a 0 (do not understand at all) to 10 (understand very clearly) response scale. A higher score indicates a stronger illness comprehensibility.

    Time frame: Baseline, Week 24

  14. Change From Baseline in BIPQ Cognitive Subscale Score at Week 24

    BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 5 items on cognitive representation of illness perception: consequences (Item 1: How much does your illness affect your life? Response range 0 \[no affect\] - 10 \[severe affect\]), timeline (Item 2: How long do you think your illness will continue? Response range 0 \[a very short time\] - 10 \[forever\]), personal control (Item 3: How much control do you feel you have over your illness? Response range 0 \[no control\] - 10 \[extreme amount of control\]), treatment control (Item 4: How much do you think your treatment can help your illness? Response range 0 \[not at all\] - 10 \[extremely helpful\]), and identity (Item 5: How much do you experience symptoms from your illness? Response range 0 \[no symptoms\] - 10 \[severe symptoms\]). Total BIPQ Cognitive Subscale Score was the sum of all item score and ranged from 0 to 50. A higher score indicates stronger illness perception.

    Time frame: Baseline, Week 24

  15. Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24

    BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 2 items on emotional representation: concern (Item 6: How concerned are you about your illness? Response range 0 \[not at all concerned\] - 10 \[extremely concerned\]) and emotions (Item 8: How much does your illness affect you emotionally; for example, does it make you angry, scared, upset or depressed? Response range 0 \[not at all affected emotionally\] - 10 \[extremely affected emotionally\]). Total BIPQ Emotional Subscale Score was the sum of above 2 items score and ranged from 0 to 20. A higher score indicates extreme emotional representation.

    Time frame: Baseline, Week 24

  16. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24

    WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

    Time frame: Baseline, Week 24

  17. System Usability Scale (SUS) Overall Score for DS Group

    The SUS was used to explore device acceptability and usability for participants in the DS group. It covered a variety of aspects of system usability, such as the need for support, training, and complexity, and thus giving a global view of subjective assessments of usability. It was a 10-question tool (with five response options; from 1=strongly disagree to 5=strongly agree) that provided a composite measure, ranging from 0 to 100, of the overall usability of the system being studied. Higher scores represent better usability level for the tool.

    Time frame: Week 24

  18. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. Number of participants with any AEs, and device-related AEs has been reported.

    Time frame: Baseline up to Week 26

07

Results

Posted Mar 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneStandard of Care (SoC)Digital System (DS)
Started185242
Safety analysis set185224
Completed173183
Not completed1259
Withdrew: Adverse event19
Withdrew: Withdrawal by subject215
Withdrew: Withdrawal by parent/guardian01
Withdrew: Non-compliance with study drug02
Withdrew: Protocol deviation011
Withdrew: Lost to follow-up913
Withdrew: Other than specified08

Outcome measures

PrimaryNumber of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control

A well-controlled asthma was defined as an Asthma Control Test (ACT) score of greater than or equal to 20. Clinically important improvement in asthma control was defined by an increase of at least 3 ACT units from baseline. The ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The ACT included 5 items that assessed daytime and nighttime asthma symptoms, use of reliever medication, and impact of asthma on daily functioning. Each item in the ACT was scored on a 5-point scale ranging from 1 (poor control of asthma) to 5 (well control of asthma), with summation of all items providing scores ranging from 5 to 25. The scores span the continuum of poor control of asthma (score of 5) to complete control of asthma (score of 25), with a cutoff score of 19 and below indicating participants with poorly controlled asthma.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control
ParticipantsStandard of Care (SoC)Digital System (DS)
Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control112134
Statistical analysis
  • Standard of Care (SoC) vs Digital System (DS) · Odds ratio (or): 1.35
SecondaryNumber of Discussions Between Participant and Investigational Center Healthcare Professional (iHCP) Regarding Inhaler Technique or Adherence

Number of participants who had discussions with iHCP regarding inhaler technique or adherence are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Discussions Between Participant and Investigational Center Healthcare Professional (iHCP) Regarding Inhaler Technique or Adherence
ParticipantsStandard of Care (SoC)Digital System (DS)
0 discussion9055
1 discussion3338
2 discussions5055
3 discussions49
4 discussions014
5 discussions14
6 discussions04
7 discussions01
8 discussions06
10 discussions05
12 discussions02
13 discussions01
14 discussions01
15 discussions01
16 discussions01
17 discussions01
18 discussions01
19 discussions04
20 discussions01
21 discussions02
22 discussions01
23 discussions01
26 discussions01
29 discussions01
SecondaryNumber of Decreased Doses of Inhaled Medication

Number of participants who received decreased dose of inhaled medication during the 24-week treatment period are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Decreased Doses of Inhaled Medication
ParticipantsStandard of Care (SoC)Digital System (DS)
Number of Decreased Doses of Inhaled Medication00
SecondaryNumber of Increased Doses of Inhaled Medication

Number of participants who received increased dose of inhaled medication during the 24-week treatment period are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Increased Doses of Inhaled Medication
ParticipantsStandard of Care (SoC)Digital System (DS)
No increased doses173200
1 increased dose510
SecondaryNumber of Changes to Different Inhaled Medication

Number of participants who received different inhaled medication during the 24-week treatment period are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Changes to Different Inhaled Medication
ParticipantsStandard of Care (SoC)Digital System (DS)
No change to different inhaled medication175187
1 change to different inhaled medication323
SecondaryNumber of Additional Inhaled Medication

Number of participants who received additional inhaled medication during the 24-week treatment period are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Additional Inhaled Medication
ParticipantsStandard of Care (SoC)Digital System (DS)
No additional inhaled medication173206
1 additional inhaled medication44
2 additional inhaled medications10
SecondaryNumber of Addition of a Systemic Corticosteroid Medication for Asthma Therapy

Number of participants who received additional systemic corticosteroid medication for asthma therapy during the 24-week treatment period are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Addition of a Systemic Corticosteroid Medication for Asthma Therapy
ParticipantsStandard of Care (SoC)Digital System (DS)
No addition of a systemic corticosteroid medication for asthma therapy173201
1 addition of a systemic corticosteroid medication for asthma therapy37
2 addition of a systemic corticosteroid medications for asthma therapy01
3 addition of a systemic corticosteroid medications for asthma therapy21
SecondaryFrequency of Intervention to Manage Comorbid Conditions Associated With Poor Asthma Control

Number of participants with different frequency of intervention to manage comorbid conditions such as Gastroesophageal Reflux Disease (GERD) and Sinusitis are reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Frequency of Intervention to Manage Comorbid Conditions Associated With Poor Asthma Control
ParticipantsStandard of Care (SoC)Digital System (DS)
No intervention to manage comorbid conditions169199
Interventions taken 1 time to manage comorbid conditions77
Interventions taken 2 times to manage comorbid conditions24
SecondaryChange From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group
Time frame:
Baseline, Week 24
Reported as:
Mean · micrograms (μg)
Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group
micrograms (μg)Digital System (DS)
Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group-12.26 ± 59.199
SecondaryChange From Baseline in the Number of SABA-free Days at Week 24 for the DS Group

Number of days a participant did not use the rescue medication in a week are reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · days
Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group
daysDigital System (DS)
Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group0.4 ± 1.94
SecondaryChange From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group

Adherence to maintenance treatment was defined as the percentage of actual inhalation doses taken out of the total number of inhalation doses prescribed over the 24- week treatment period.

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of inhalation
Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group
percentage of inhalationDigital System (DS)
Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group-10.87 ± 31.717
SecondaryChange From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24

The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ concern is a 6-item scale assessing participant's concerns about potential adverse consequences (range: 1=strongly disagree to 5=strongly agree). Participants indicated their degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24-0.8 ± 3.34-0.9 ± 4.06
SecondaryChange From Baseline in BMQ Necessity Subscale Score at Week 24

The BMQ was used to assess cognitive representations of medicine. The Beliefs About Medicines Questionnaire-Specific 11 (BMQ-S11) was an 11-item questionnaire that assessed the representation of medication prescribed for personal use and the BMQ-General assesses beliefs about medicines in general. BMQ necessity is a 5-item scale assessing participant's beliefs about necessity of medications for controlling disease. Participants indicated degree of agreement on a 5-point scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items were summed, divided by the total number of items and multiplied by 5 to give a total score ranging from 5 to 25 (higher scores=stronger beliefs).

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in BMQ Necessity Subscale Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Change From Baseline in BMQ Necessity Subscale Score at Week 24-0.4 ± 3.27-1.3 ± 3.86
SecondaryChange From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24

The BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. Only one item assesses illness comprehensibility or coherence of illness (Item 7: How well do you feel you understand your illness?). This item was rated using a 0 (do not understand at all) to 10 (understand very clearly) response scale. A higher score indicates a stronger illness comprehensibility.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24-0.0 ± 1.650.1 ± 2.04
SecondaryChange From Baseline in BIPQ Cognitive Subscale Score at Week 24

BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 5 items on cognitive representation of illness perception: consequences (Item 1: How much does your illness affect your life? Response range 0 \[no affect\] - 10 \[severe affect\]), timeline (Item 2: How long do you think your illness will continue? Response range 0 \[a very short time\] - 10 \[forever\]), personal control (Item 3: How much control do you feel you have over your illness? Response range 0 \[no control\] - 10 \[extreme amount of control\]), treatment control (Item 4: How much do you think your treatment can help your illness? Response range 0 \[not at all\] - 10 \[extremely helpful\]), and identity (Item 5: How much do you experience symptoms from your illness? Response range 0 \[no symptoms\] - 10 \[severe symptoms\]). Total BIPQ Cognitive Subscale Score was the sum of all item score and ranged from 0 to 50. A higher score indicates stronger illness perception.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in BIPQ Cognitive Subscale Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Change From Baseline in BIPQ Cognitive Subscale Score at Week 24-2.5 ± 5.51-3.3 ± 6.83
SecondaryChange From Baseline in BIPQ Emotional Representations Subscale Score at Week 24

BIPQ was a 9-item questionnaire designed to rapidly assess cognitive and emotional representations of illness. It comprised 2 items on emotional representation: concern (Item 6: How concerned are you about your illness? Response range 0 \[not at all concerned\] - 10 \[extremely concerned\]) and emotions (Item 8: How much does your illness affect you emotionally; for example, does it make you angry, scared, upset or depressed? Response range 0 \[not at all affected emotionally\] - 10 \[extremely affected emotionally\]). Total BIPQ Emotional Subscale Score was the sum of above 2 items score and ranged from 0 to 20. A higher score indicates extreme emotional representation.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24-1.1 ± 4.01-1.3 ± 3.98
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24

WPAI-asthma is a self-administered instrument to measure asthma-specific performance impairment of work and regular daily activity within the last 7 days and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score ranged from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24
units on a scaleStandard of Care (SoC)Digital System (DS)
Absenteeism-3.56 ± 14.38-0.05 ± 8.61
Presenteeism-10.98 ± 24.50-10.43 ± 18.57
Work productivity loss-12.18 ± 26.25-9.87 ± 19.16
Activity impairment-11.22 ± 23.81-15.33 ± 21.48
SecondarySystem Usability Scale (SUS) Overall Score for DS Group

The SUS was used to explore device acceptability and usability for participants in the DS group. It covered a variety of aspects of system usability, such as the need for support, training, and complexity, and thus giving a global view of subjective assessments of usability. It was a 10-question tool (with five response options; from 1=strongly disagree to 5=strongly agree) that provided a composite measure, ranging from 0 to 100, of the overall usability of the system being studied. Higher scores represent better usability level for the tool.

Time frame:
Week 24
Reported as:
Mean · units on a scale
System Usability Scale (SUS) Overall Score for DS Group
units on a scaleDigital System (DS)
SUS Overall Score (completed by participants)70.0 ± 19.10
Site SUS Overall Score (completed by site)73.2 ± 18.03
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. Number of participants with any AEs, and device-related AEs has been reported.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsStandard of Care (SoC)Digital System (DS)
Any AEs5677
Device-related AEs03

Adverse events

Collected over Baseline up to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care (SoC)0/185 (0%)4/185 (2.2%)23/185 (12.4%)
Digital System (DS)0/224 (0%)6/224 (2.7%)24/224 (10.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventStandard of Care (SoC)Digital System (DS)
Coronary artery diseaseCardiac disorders1/1850/224
PancreatitisGastrointestinal disorders1/1850/224
Cholecystitis chronicHepatobiliary disorders1/1850/224
Ear infectionInfections and infestations1/1850/224
AsthmaRespiratory, thoracic and mediastinal disorders1/1851/224
AppendicitisInfections and infestations0/1851/224
COVID-19 pneumoniaInfections and infestations0/1851/224
Oral candidiasisInfections and infestations0/1851/224
ArthralgiaMusculoskeletal and connective tissue disorders0/1851/224
Endometrial cancer stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1851/224
Most frequent other events
Most frequent other events
EventStandard of Care (SoC)Digital System (DS)
COVID-19Infections and infestations15/1856/224
AsthmaRespiratory, thoracic and mediastinal disorders11/18518/224

Baseline characteristics

Intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Standard of Care (SoC)Digital System (DS)Total
Mean46.7 ± 17.7246.9 ± 18.3646.8 ± 18.06
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care (SoC)Digital System (DS)Total
Female116177293
Male6965134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard of Care (SoC)Digital System (DS)Total
Hispanic or Latino6380143
Not Hispanic or Latino114157271
Unknown or Not Reported8513
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard of Care (SoC)Digital System (DS)Total
White136185321
Black or African American374582
Asian7613
American Indian or Alaska Native101
Native Hawaiian or other Pacific Islander112
Not reported246
Other112
08

Study locations

46 sites
  • Teva Investigational Site 14971
    Phoenix, Arizona 85018, United States
  • Teva Investigational Site 14974
    Fountain Valley, California 92708, United States
  • Teva Investigational Site 14982
    Los Angeles, California 90025, United States
  • Teva Investigational Site 14945
    San Diego, California 92120, United States
  • Teva Investigational Site 14946
    San Diego, California 92123, United States
  • Teva Investigational Site 14966
    Colorado Springs, Colorado 80907, United States
  • Teva Investigational Site 14962
    Wheat Ridge, Colorado 80033, United States
  • Teva Investigational Site 14943
    Aventura, Florida 33180, United States
  • Teva Investigational Site 14969
    Boynton Beach, Florida 33472, United States
  • Teva Investigational Site 14978
    Cutler Bay, Florida 33189, United States
  • Teva Investigational Site 14955
    Fort Lauderdale, Florida 33308, United States
  • Teva Investigational Site 14984
    Hialeah, Florida 33012, United States
  • Teva Investigational Site 14979
    Hialeah, Florida 33016, United States
  • Teva Investigational Site 14960
    Miami Lakes, Florida 33014, United States
  • Teva Investigational Site 14953
    Miami, Florida 33135, United States
  • Teva Investigational Site 14975
    Miami, Florida 33166-6817, United States
  • Teva Investigational Site 14944
    Miami, Florida 33173, United States
  • Teva Investigational Site 14970
    Miami, Florida 33216, United States
  • Teva Investigational Site 14981
    Sarasota, Florida 34239, United States
  • Teva Investigational Site 14951
    Tallahassee, Florida 32308-4355, United States
  • Teva Investigational Site 14942
    Savannah, Georgia 31406, United States
  • Teva Investigational Site 14947
    Boise, Idaho 83706, United States
  • Teva Investigational Site 14961
    Glenview, Illinois 60026, United States
  • Teva Investigational Site 14972
    Springfield, Illinois 62704, United States
  • Teva Investigational Site 14950
    Lexington, Kentucky 40509, United States
  • Teva Investigational Site 14949
    Owensboro, Kentucky 42301, United States
  • Teva Investigational Site 14976
    Bangor, Maine 04401, United States
  • Teva Investigational Site 14983
    White Marsh, Maryland 21162, United States
  • Teva Investigational Site 14964
    Farmington Hills, Michigan 48336, United States
  • Teva Investigational Site 14990
    Bellevue, Nebraska 68123-4303, United States
  • Teva Investigational Site 14977
    Lincoln, Nebraska 68505, United States
  • Teva Investigational Site 14957
    Toms River, New Jersey 08755, United States
  • Teva Investigational Site 14956
    Hollis, New York 11423, United States
  • Teva Investigational Site 14954
    Gastonia, North Carolina 28054, United States
  • Teva Investigational Site 14941
    Cincinnati, Ohio 45221, United States
  • Teva Investigational Site 14968
    Toledo, Ohio 43617, United States
  • Teva Investigational Site 14952
    Oklahoma City, Oklahoma 73120, United States
  • Teva Investigational Site 14958
    Oklahoma City, Oklahoma 73120, United States
  • Teva Investigational Site 14967
    Pittsburgh, Pennsylvania 15241, United States
  • Teva Investigational Site 14988
    Providence, Rhode Island 02906, United States
  • Teva Investigational Site 14989
    North Charleston, South Carolina 29420, United States
  • Teva Investigational Site 14985
    Boerne, Texas 78006, United States
  • Teva Investigational Site 14963
    Houston, Texas 77081, United States
  • Teva Investigational Site 14948
    Waco, Texas 76712, United States
  • Teva Investigational Site 14987
    Draper, Utah 84020, United States
  • Teva Investigational Site 14965
    Murray, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2022, 12 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 12 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2020
First posted
Dec 21, 2020
StartActual
Feb 16, 2021
Primary completionActual
Mar 4, 2022
CompletionActual
Mar 10, 2022
Results first posted
Mar 14, 2023
Last update
Mar 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04677959
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Feb 16, 2021
Primary completion
Mar 4, 2022
Completion
Mar 10, 2022
Results posted
Mar 14, 2023
Last update
Mar 14, 2023

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate · Albuterol

Start the discussion